CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for BioNxt Solutions Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

BioNxt Solutions Inc
Suite 270 - 1820 Fir Street
Phone: (780) 818-6422p:780 818-6422 VANCOUVER, BC  V6J 3B1  Canada Ticker: BNXTBNXT
Business Summary
BioNxt Solutions Inc. is a Canada-based bioscience company. The Company focuses on drug delivery platforms, diagnostic screening systems, and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets, and a new targeted chemotherapy platform. The targeted chemotherapy platform is designed to transform the way cytotoxic drugs are administered, by delivering active compounds directly into tumor tissue while minimizing exposure to healthy cells. Its product pipeline includes BNT23001, BNT23002, BNT24002, BNT24003, and BNT24004. BNT23001 is a sublingual Cladribine film targeting multiple sclerosis (MS), offering improved bioavailability and patient convenience. BNT23002 is a sublingual Cladribine formulation for myasthenia gravis (MG), addressing the challenges of oral medication in patients with swallowing difficulties. BNT24002 is a sublingual thin film for the treatment of lupus nephritis (LN).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202512/31/2024Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chief Executive Officer, Director HughRogers 45 11/12/2024 12/12/2017
Chief Financial Officer, Secretary, Director WolfgangProbst 11/12/2024 12/12/2018
Managing Director, Vektor Pharma TF GmbH ThomasBeckert 9/13/2019 9/13/2019
4 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Vektor Pharma TF GmbH Hauptstrae 13 Uttenweiler Germany

Business Names
Business Name
3a-diagnostics GmbH
4XT
BNXT
Vektor Pharma TF GmbH
XPHY

General Information
Number of Employees: 15 (As of 12/31/2019)
Outstanding Shares: 116,964,754 (As of 6/30/2025)
Stock Exchange: CNQ
Email Address: info@xphyto.com


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, October 31, 2025